Representation of a complex Green function on a real basis: I. General Theory

When the Hamiltonian of a system is represented by a finite matrix, constructed from a discrete basis, the matrix representation of the resolvent covers only one branch. We show how all branches can be specified by the phase of a complex unit of time. This permits the Hamiltonian matrix to be constructed on a real basis; the only duty of the basis is to span the dynamical region of space, without regard for the particular asymptotic boundary conditions that pertain to the problem of interest.Comment: about 40 pages with 5 eps-figure

Elastic scattering of protons from hydrogen atoms at energies 15-200keV

Differential and integrated cross sections for the elastic process H^+ + H(1s) → H^+ + H(1s) were calculated with the use of results of coupled-state calculations in the energy range 15-200 keV. Results are presented and, at 60 keV, compared favorably with preliminary experimental data. The asymptotic form of the elastic amplitude for b≫a_0 (where b is the impact parameter) is derived for the two cases λ≪1 and λ≫1, where λ is the ratio of the collision duration to the orbital period. The asymptotic form for λ≫1 provides a useful test on the numerical accuracy of the amplitudes

Application of an extremum principle to the variational determination of the generalized oscillator strengths of helium

Variational principles have been used extensively for estimating some given functional F(φ, φ†) where the functions φ and φ† are well defined by a set of differential equations and boundary conditions but cannot be determined exactly. The variational principle for the estimation of a matrix element of an arbitrary Hermitian operator W involves not only the trial wave functions φt but also trial auxiliary Lagrange functions Lt; the Lt depend on the φt and on W. To determine the parameters in the Lt efficiently, a functional M(Ltt) is constructed which is an extremum for Ltt=Lt. The technique was recently used successfully in the variational estimation of two diagonal matrix elements. We here use this technique for the variational estimation of an off-diagonal matrix element, the generalized oscillator strengths of helium for the transition between the ground state and the excited 21P state. Two Lt\u27s must be determined. Our results on helium indicate that variational estimates are a significant improvement over the first-order estimates. The results are also compared with those obtained nonvariationally using more elaborate ground-and excited-state wave functions; the comparison represents a check on the method. It is not yet clear which of the two approaches is more efficient

Distorted-wave Born approximation for inelastic collisions: Application to electron capture by positrons from hydrogen atoms

We have re-examined the distorted-wave Born approximation for inelastic collisions. We find that the distortion in the relative motion of the collision partners cannot be neglected even for high-energy ion-atom collisions. Furthermore, if the distortion in the relative motion is not treated exactly, post-prior discrepancies will occur. We have applied the distorted-wave Born approximation, with distortion included through first order, to ground-state-to-ground-state electron capture by positrons from hydrogen atoms. The results are presented in this paper. We have also examined the nonrelativistic asymptotic behavior of the cross section for electron capture from hydrogen by positrons incident with a speed v∼∞. We find that, for e2ℏv≪1, capture occurs primarily to states of positronium that have an odd orbital-angular-momentum quantum number. It follows that the cusp signifying charge transfer to the continuum will, for positron impact, be symmetric when e2ℏv≪1

Exact field ionization rates in the barrier suppression-regime from numerical TDSE calculations

Numerically determined ionization rates for the field ionization of atomic hydrogen in strong and short laser pulses are presented. The laser pulse intensity reaches the so-called "barrier suppression ionization" regime where field ionization occurs within a few half laser cycles. Comparison of our numerical results with analytical theories frequently used shows poor agreement. An empirical formula for the "barrier suppression ionization"-rate is presented. This rate reproduces very well the course of the numerically determined ground state populations for laser pulses with different length, shape, amplitude, and frequency. Number(s): 32.80.RmComment: Enlarged and newly revised version, 22 pages (REVTeX) + 8 figures in ps-format, submitted for publication to Physical Review A, WWW: http://www.physik.tu-darmstadt.de/tqe

Neuropsychiatric manifestations and sleep disturbances with dolutegravir-based antiretroviral therapy versus standard of care in children and adolescents: a secondary analysis of the ODYSSEY trial

BACKGROUND: Cohort studies in adults with HIV showed that dolutegravir was associated with neuropsychiatric adverse events and sleep problems, yet data are scarce in children and adolescents. We aimed to evaluate neuropsychiatric manifestations in children and adolescents treated with dolutegravir-based treatment versus alternative antiretroviral therapy. METHODS: This is a secondary analysis of ODYSSEY, an open-label, multicentre, randomised, non-inferiority trial, in which adolescents and children initiating first-line or second-line antiretroviral therapy were randomly assigned 1:1 to dolutegravir-based treatment or standard-of-care treatment. We assessed neuropsychiatric adverse events (reported by clinicians) and responses to the mood and sleep questionnaires (reported by the participant or their carer) in both groups. We compared the proportions of patients with neuropsychiatric adverse events (neurological, psychiatric, and total), time to first neuropsychiatric adverse event, and participant-reported responses to questionnaires capturing issues with mood, suicidal thoughts, and sleep problems. FINDINGS: Between Sept 20, 2016, and June 22, 2018, 707 participants were enrolled, of whom 345 (49%) were female and 362 (51%) were male, and 623 (88%) were Black-African. Of 707 participants, 350 (50%) were randomly assigned to dolutegravir-based antiretroviral therapy and 357 (50%) to non-dolutegravir-based standard-of-care. 311 (44%) of 707 participants started first-line antiretroviral therapy (ODYSSEY-A; 145 [92%] of 157 participants had efavirenz-based therapy in the standard-of-care group), and 396 (56%) of 707 started second-line therapy (ODYSSEY-B; 195 [98%] of 200 had protease inhibitor-based therapy in the standard-of-care group). During follow-up (median 142 weeks, IQR 124–159), 23 participants had 31 neuropsychiatric adverse events (15 in the dolutegravir group and eight in the standard-of-care group; difference in proportion of participants with ≥1 event p=0·13). 11 participants had one or more neurological events (six and five; p=0·74) and 14 participants had one or more psychiatric events (ten and four; p=0·097). Among 14 participants with psychiatric events, eight participants in the dolutegravir group and four in standard-of-care group had suicidal ideation or behaviour. More participants in the dolutegravir group than the standard-of-care group reported symptoms of self-harm (eight vs one; p=0·025), life not worth living (17 vs five; p=0·0091), or suicidal thoughts (13 vs none; p=0·0006) at one or more follow-up visits. Most reports were transient. There were no differences by treatment group in low mood or feeling sad, problems concentrating, feeling worried or feeling angry or aggressive, sleep problems, or sleep quality. INTERPRETATION: The numbers of neuropsychiatric adverse events and reported neuropsychiatric symptoms were low. However, numerically more participants had psychiatric events and reported suicidality ideation in the dolutegravir group than the standard-of-care group. These differences should be interpreted with caution in an open-label trial. Clinicians and policy makers should consider including suicidality screening of children or adolescents receiving dolutegravir

Dolutegravir twice-daily dosing in children with HIV-associated tuberculosis: a pharmacokinetic and safety study within the open-label, multicentre, randomised, non-inferiority ODYSSEY trial

Background: Children with HIV-associated tuberculosis (TB) have few antiretroviral therapy (ART) options. We aimed to evaluate the safety and pharmacokinetics of dolutegravir twice-daily dosing in children receiving rifampicin for HIV-associated TB. Methods: We nested a two-period, fixed-order pharmacokinetic substudy within the open-label, multicentre, randomised, controlled, non-inferiority ODYSSEY trial at research centres in South Africa, Uganda, and Zimbabwe. Children (aged 4 weeks to <18 years) with HIV-associated TB who were receiving rifampicin and twice-daily dolutegravir were eligible for inclusion. We did a 12-h pharmacokinetic profile on rifampicin and twice-daily dolutegravir and a 24-h profile on once-daily dolutegravir. Geometric mean ratios for trough plasma concentration (Ctrough), area under the plasma concentration time curve from 0 h to 24 h after dosing (AUC0–24 h), and maximum plasma concentration (Cmax) were used to compare dolutegravir concentrations between substudy days. We assessed rifampicin Cmax on the first substudy day. All children within ODYSSEY with HIV-associated TB who received rifampicin and twice-daily dolutegravir were included in the safety analysis. We described adverse events reported from starting twice-daily dolutegravir to 30 days after returning to once-daily dolutegravir. This trial is registered with ClinicalTrials.gov (NCT02259127), EudraCT (2014–002632-14), and the ISRCTN registry (ISRCTN91737921). Findings: Between Sept 20, 2016, and June 28, 2021, 37 children with HIV-associated TB (median age 11·9 years [range 0·4–17·6], 19 [51%] were female and 18 [49%] were male, 36 [97%] in Africa and one [3%] in Thailand) received rifampicin with twice-daily dolutegravir and were included in the safety analysis. 20 (54%) of 37 children enrolled in the pharmacokinetic substudy, 14 of whom contributed at least one evaluable pharmacokinetic curve for dolutegravir, including 12 who had within-participant comparisons. Geometric mean ratios for rifampicin and twice-daily dolutegravir versus once-daily dolutegravir were 1·51 (90% CI 1·08–2·11) for Ctrough, 1·23 (0·99–1·53) for AUC0–24 h, and 0·94 (0·76–1·16) for Cmax. Individual dolutegravir Ctrough concentrations were higher than the 90% effective concentration (ie, 0·32 mg/L) in all children receiving rifampicin and twice-daily dolutegravir. Of 18 children with evaluable rifampicin concentrations, 15 (83%) had a Cmax of less than the optimal target concentration of 8 mg/L. Rifampicin geometric mean Cmax was 5·1 mg/L (coefficient of variation 71%). During a median follow-up of 31 weeks (IQR 30–40), 15 grade 3 or higher adverse events occurred among 11 (30%) of 37 children, ten serious adverse events occurred among eight (22%) children, including two deaths (one tuberculosis-related death, one death due to traumatic injury); no adverse events, including deaths, were considered related to dolutegravir. Interpretation: Twice-daily dolutegravir was shown to be safe and sufficient to overcome the rifampicin enzyme-inducing effect in children, and could provide a practical ART option for children with HIV-associated TB